Indications
Treatment of breast cancer, non-small cell lung cancer, renal cell cancer, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, platinum-sensitive epithelial ovarian, fallopian tube or primary
Composition
- Active substance
- bevacizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kyomarc
- Active substance
- bevacizumab
- ATC code
- L01XC07
- Therapeutic area
- Carcinoma, Renal Cell, Carcinoma, Bronchogenic, Fallopian Tube Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms
- Marketing authorisation holder